Petrovax Pharm continues building up export presence
In 2018, Petrovax Pharm continued exports to the EAEU, EU, and Iran. As of 2018, exports amounted to about 1B RUB accounting for 11.8% in the company’s total sales.
Currently, Petrovax Pharm supplies Grippol® plus vaccine to six countries (Belarus, Kazakhstan, Iran, Kyrgyzstan, Turkmenistan, and Uzbekistan) under the state-funded free vaccination programs. Over the past 3 years (2016–2018), Petrovax Pharm’s exports of the influenza vaccine for free immunization of the population exceeded 18M shots.
The market launch of Grippol® Quadrivalent vaccine provides for new opportunities in developing the company’s exports.
Presently, Petrovax Pharm is the first and only Russian pharmaceutical manufacturer to supply an influenza vaccine to Iran. Since 2016, 1,35M shots of trivalent flu vaccine Grippol® plus were exported to Iran.
Polyoxidonium® is among the company’s successfully exported pharmaceutical products.
Thus, in 2017, the company was issued a positive Post-Authorisation Safety Study (PASS) report for Polyoxidonium® in the EU (Slovakia); Petrovax initiated this study in 2016. The PASS has confirmed a high safety profile and good tolerability of Polyoxidonium® among the patients.
Petrovax Pharm also has long-standing partnership relations with Ukraine. Since 2004, the company has supplied Polyoxidonium® and Longidaze® to the Ukrainian market. In 2012, Petrovax was issued an EU GMP certificate for its manufacturing and Quality Management System by Ukraine’s state regulator.
Petrovax Pharm’s export business has been running since 2002. Today, the company exports to 12 countries including Belarus, Kazakhstan, Kyrgyzstan, Ukraine, Turkmenistan, Azerbaijan, Moldova, Armenia, Georgia, Uzbekistan, Slovakia, and Iran. The exported products include Grippol® plus, Polyoxidonium®, Longidaze®, and Imoferaza®. Belarus, Kazakhstan, and Uzbekistan account for the highest percentage in the company’s export structure. The company has an apparent competitive edge for export activities, i.e. a branded product portfolio, state-of-the-art high-tech manufacturing facilities complying with the applicable international GMPs, and an investment-based development strategy.